PNH News & Events

Explore the latest news, events and information related to paroxysmal nocturnal hemoglobinuria (PNH) and the clinical development of APL-2.

AAMDS Webinar - PNH: Intravascular Hemolysis and Extravascular Hemolysis

Apellis is excited to support an upcoming AAMDS webinar, presented by Dr. Thomas DeLoughery from Oregon Health Sciences University (OHSU), on May 9, 2019 at 1:00 PM EDT. This educational webinar will focus on both intravascular and extravascular hemolysis in PNH, as well as symptoms, potential treatment, and the effect intravascular and extravascular hemolysis have on PNH patients. Registration for this webinar is free. To learn more about this upcoming webinar, and to register, click the link below!

Read More

APL-2 Receives Fast Track Designation the Treatment of PNH

Apellis Pharmaceuticals’ APL-2 Receives Fast Track Designation from the FDA for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria

Read More

AAMDS 2019 Patient & Family Conference: Albuquerque, NM

Apellis is proud to support the AAMDS 2019 Patient & Family Conference taking place in Albuquerque, NM on March 30, 2019. Registration for this event is free, and will provide you an opportunity to meet and interact with national and international experts in your disease, as well as other patients that might share similar experiences with their disease as you. To learn more about the event, and to register, click the link below!

Read More

Women and PNH – An AAMDS Webinar

On April 22nd, Dr. Jamile Shammo from Rush University Medical Center, will host a webinar to discuss PNH and special concerns for women. In addition to Dr. Shammo’s talk, participants will also have the opportunity to ask Dr. Shammo questions. To learn more about the webinar, and to register, please click the link below.

Read More

AAMDS March for Marrow 5k Run & Walk – Los Angeles, CA

Apellis will be in Los Angeles on April 27th for the AAMDS March for Marrow 5K run and walk to help raise awareness for aplastic anemia, myelodysplastic syndromes (MDS), paroxysmal nocturnal hemoglobinuria (PNH) and related bone marrow failure diseases. Click the link below for details about the March for Marrow in Los Angeles, including the location, an agenda for the day, and links to register!

Read More

NORD Rare Disease Day 2019

Join Apellis in raising awareness for the millions of Americans whose lives are affected by rare diseases. The National Organization for Rare Disorders (NORD) is the official sponsor of Rare Disease Day in the United States. Rare Disease Day takes place on the last day of February each year. To learn more about Rare Disease Day, and how you can get involved, click the link below!

Read More

March for Marrow Walk - Houston 2019

Join Apellis and the Aplastic Anemia and MDS International Foundation for the 2019 Houston March for Marrow on March 30th, 2019. AAMDS is dedicated to providing education, support, and hope for patients living with aplastic anemia, myelodysplastic syndromes (MDS), paroxysmal nocturnal hemoglobinuria (PNH) and related bone marrow failure diseases. To learn more about the March for Marrow Walk in Houston, and how you can get involved, click the link below!

Read More

AAMDS "Living with Aplastic Anemia, MDS, PNH” Patient and Family Conferences

The AAMDS International Foundation is hosting national “Living with Aplastic Anemia, MDS, PNH” patient and family conferences in cities around the country. These conferences are free to attend, and they offer the opportunity to interact with and learn from leading medical experts, other patients and caregivers. To learn more about upcoming Patient and Family Conferences in 2019, including dates, locations and registration information, click the link below!

Read More

PNH Data Presented at ASH 2018

Apellis Pharmaceuticals presents updated data from a clinical study of APL-2 in patients with paroxysmal nocturnal hemoglobinuria (PNH) at the American Society of Hematolgy (ASH) 2018 Annual Meeting.

Read More

ASH 2018 Poster Presentations Announced

Apellis Pharmaceuticals announces poster presentations at the American Society of Hematology (ASH) 2018 Annual Meeting.

Read More

APL-2 Monotherapy in PNH

Apellis Pharmaceuticals announces that all four severely anemic Soliris™-treated patients with paroxysmal nocturnal hemoglobinuria (PNH) in ongoing phase 1b trial have been transitioned to APL-2 monotherapy.

Read More

First Patient Enrolled in PEGASUS Phase 3 Clinical Trial in Paroxysmal Nocturnal Hemoglobinuria (PNH)

Apellis Pharmaceuticals Announces First Patient Enrolled in Phase 3 APL-2 Head-to-Head Study in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated with Soliris™

Read More

PHAROAH & PADDOCK Phase 1b Trial Update

Apellis Pharmaceuticals Provides Update on Two Phase Ib Trials for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Read More